Dupilumab for the treatment of prurigo nodularis
Prurigo nodularis (PN) is a chronic, intensely pruritic dermatosis driven by neural and immune dysregulation, with historically limited FDA-approved treatment options. In September 2022, dupilumab became the first FDA-approved therapy for PN. To review the clinical efficacy of dupilumab in PN, with...
Збережено в:
| Автори: | , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Taylor & Francis Group
2026-12-01
|
| Серія: | Future Rare Diseases |
| Предмети: | |
| Онлайн доступ: | https://www.tandfonline.com/doi/10.1080/23995270.2026.2664390 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|